Litcius/Paper detail

New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination

Joshua Kaminetsky, Donald Rudikoff

2021Clinical Case Reports40 citationsDOIOpen Access PDF

Abstract

The COVID-19 mRNA vaccines not only provide remarkable protection but also have been characterized by an overall safe and well-tolerated side effect profile. Herein, we discuss a rare but manageable cutaneous reaction to COVID vaccination in order to further characterize dermatologic reactions and stress the continued vaccination of eligible patients.

Topics & Concepts

MedicineVaccinationCoronavirus disease 2019 (COVID-19)VitiligoDermatology2019-20 coronavirus outbreakMessenger RNASevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyImmunologyInternal medicineOutbreakDiseaseGeneChemistryBiochemistryInfectious disease (medical specialty)Cell Adhesion Molecules ResearchImmunotherapy and Immune ResponsesHerpesvirus Infections and Treatments
New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination | Litcius